![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The financing aims to fund the clinical development of Neurosterix’s lead program, which is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulators for the treatment of patients suffering from schizophrenia.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund II
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 03, 2024